Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citalopram for functional chest pain
NL-OMON50787Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in functional chest pain (FCP) comparing Citalopram with Placebo (2 arms). Primary endpoint: Global assessment of patient-reported reduction in chest pain. Started Jan 2022; status: active, not recruiting.
02
Drugs
citalopram
03
Conditions
functional chest pain (FCP)
Beyond the preview
Go deeper on NL-OMON50787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50787.